1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (CRPC)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (CRPC)

New Protocol: Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer (CRPC)
Study:
  • Phase III, randomized, double-blind, placebo-controlled, multicenter (MAGNITUDE)
  • Treatment naïve, Homologous Recombination Repair positive (HRR+) mCRPC
  • Niraparib + Abiraterone acetate + prednizon (Niraparib + AAP group, n=212) vs. PBO + Abirateron acetate + prednizon (PBO + AAP group, n=211)
Efficacy:
  • In BRCA1/2 mutant subgroup: mrPFS: 16.6 vs. 10.9 mos, p=0.001
  • In non-BRCA1/2 mutant HRR subgroup mrPFS: 16.5 vs. 13.5 mos, p=0.022
Safety:
  • Any grade: anemia (46.2% vs. 20.4%), hypertension (31.1% vs. 20.9%), constipation (30.7% vs. 13.7%), fatigue (26.4% vs.16.6%)
  • Grade≥3 AEs: Anemia (28.3% vs. 7.6%), hypertension (14.6% vs. 12.3%).

J Clin Oncol 2023; 28 MAR

Chi N. Kim et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

http://doi.org/10.1200/JCO.22.01649

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More